Cost Saving Opportunities in NSCLC Therapy by Optimized Diagnostics

With an incidence of 68 new cases per 100,000 people per year, an estimated total number of up to 350,000 new non-small-cell lung cancer (NSCLC) cases are diagnosed each year in the European Union. Up to 10% of NSCLC patients are eligible for therapy with novel ALK (anaplastic lymphoma kinase) inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Nenadić, Ilija, Staber, Janine, Dreier, Susanne, Simons, Guus, Schildgen, Verena, Brockmann, Michael, Schildgen, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532624/
https://www.ncbi.nlm.nih.gov/pubmed/28696381
http://dx.doi.org/10.3390/cancers9070088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532624/
https://www.ncbi.nlm.nih.gov/pubmed/28696381
http://dx.doi.org/10.3390/cancers9070088

Ejemplares similares